Evidence map›Paper›PMID 34028822›Full record

ArticleThe Hastings Center report2021

Gene Editing: How Can You Ask "Whether" If You Don't Know "How"?

Bryan Cwik

Abstract read
In one paragraph

Article in The Hastings Center report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bryan Cwik

Funding

Intergenerational Monitoring in Clinical Trials of Germline Gene Editing: Ethical, Legal, and Social IssuesR03HG010417 · NHGRI · PORTLAND STATE UNIVERSITY · PI CWIK, BRYAN · 2018 to 2019
$149k
NHGRI NIH HHS R03 HG010417
6 · The paper itself

Abstract

Though questions about whether gene editing should be done at all have dominated ethical discussion, a literature about how it can be done ethically has been growing. Work on responsible translational pathways for human germline gene editing has been criticized for focusing on the wrong questions. But questions about responsible translational pathways-questions about how gene editing could be done ethically-are, in an important sense, prior to questions about whether it is desirable and permissible. Asking "whether" questions about gene editing requires a model of what responsible clinical use of gene editing would look like.

Indexed as

Gene EditingGerm CellsHumansMoralsemerging medical technologiesgene editingreproductive medicineresearch ethicstranslational research

Identifiers

PMID34028822
PMCPMC8260147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.